Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement - HIV/AIDS

University of Ottawa

$100,000.00

Uncovering the Unexpected Role of APOBEC3 Mutagenesis in HIV-1 Latency

EF 2017-18

Résumé
HIV latency continues to be a major hurdle in eradicating this terrible disease. Combination antiretroviral therapy (cART) is extremely effective at suppressing HIV infection and replication, but fails to eliminate long-lived immune cells infected with a dormant virus. These cells are termed latently infected because dormant viruses can be reactivated in periods of cellular stress or when a patient ceases cART. Therefore, latently infected cells constitute one of the most formidable obstacles to finding a cure for HIV. Several cellular mechanisms have been identified that can partially explain how some cells become latently infected, but the complete scheme of latency-inducing factors has not yet been extensively defined. We will investigate how the host's own immune system may indirectly contribute to the creation of a subset of latently infected cells. APOBEC3 (A3) proteins are expressed in host immune cells targeted by HIV and normally constitute an important barrier to retrovirus infection. They do so by inducing intense and inactivating mutations in HIV DNA. However, low levels of mutations may in some instances help the virus evolve and evade immune detection. Our preliminary laboratory results indicate that low intensity mutations caused by A3 proteins constitutes a new and unexpected way for HIV to become latent. The research we propose will investigate the exact way A3 mutations cause HIV latency. Furthermore, we will use A3-mutated latent viruses that we have isolated to test the efficacy of various latency-reversing agents in an HIV-infected animal model. Our research will improve the design and testing of the next generation of latency-reversing agents and identify prognostic mutations in the viral DNA to help predict their effectiveness.
Programme
Project Grant - Priority Announcement - HIV/AIDS
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
384603
Name
Langlois Marc-Andre
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Uncovering the Unexpected Role of APOBEC3 Mutagenesis in HIV-1 Latency
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement - HIV/AIDS
Keyworddelim
Apobec3; Hiv Latency; Latency Reversal; Molecular Virology
Abstract
HIV latency continues to be a major hurdle in eradicating this terrible disease. Combination antiretroviral therapy (cART) is extremely effective at suppressing HIV infection and replication, but fails to eliminate long-lived immune cells infected with a dormant virus. These cells are termed latently infected because dormant viruses can be reactivated in periods of cellular stress or when a patient ceases cART. Therefore, latently infected cells constitute one of the most formidable obstacles to finding a cure for HIV. Several cellular mechanisms have been identified that can partially explain how some cells become latently infected, but the complete scheme of latency-inducing factors has not yet been extensively defined. We will investigate how the host's own immune system may indirectly contribute to the creation of a subset of latently infected cells. APOBEC3 (A3) proteins are expressed in host immune cells targeted by HIV and normally constitute an important barrier to retrovirus infection. They do so by inducing intense and inactivating mutations in HIV DNA. However, low levels of mutations may in some instances help the virus evolve and evade immune detection. Our preliminary laboratory results indicate that low intensity mutations caused by A3 proteins constitutes a new and unexpected way for HIV to become latent. The research we propose will investigate the exact way A3 mutations cause HIV latency. Furthermore, we will use A3-mutated latent viruses that we have isolated to test the efficacy of various latency-reversing agents in an HIV-infected animal model. Our research will improve the design and testing of the next generation of latency-reversing agents and identify prognostic mutations in the viral DNA to help predict their effectiveness.
Competitiondate
201803
Approvedterm2
1 yr 0 mth
Pinamesdelim
Langlois, Marc-Andre
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~